Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and approve 1. Un-audited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical has informed BSE that its Board of Directors will meet on Wednesday, 4 February 2026 at the company's corporate office. The agenda includes approval of the unaudited financial results for the quarter ended 31 December 2025 (Q3 FY26), along with the Limited Review Report from auditors. The notice also includes a standard catch-all item for any other business with the Chair's permission. The filing is made under SEBI LODR Regulations 29 and 33, which govern disclosure of financial results. No actual financial numbers have been disclosed yet — these will come after the board meeting.
This is a routine procedural filing ahead of results and does not directly affect the stock price. Investors should watch for the actual Q3 results on or after 4 February 2026 for any meaningful business signals.